Abstract
The global health challenge of diabetes mellitus continues to escalate, affecting millions of people worldwide. Managing this chronic condition necessitates lifelong treatment to control hyperglycemia and prevent complications. The delivery of antidiabetic medications can be improved by solid lipid nanoparticles (SLNs). This review provides an overview of current research on antidiabetic-loaded SLNs, summarizing their efficacy, safety, and challenges. Various antidiabetic agents, including insulin, metformin, sulfonylureas, and GLP-1 agonists, have been successfully encapsulated into SLNs, offering improved pharmacokinetic profiles and therapeutic outcomes. Despite their potential, optimization of SLN formulations, scale-up challenges, and translation to clinical practice remain areas requiring further investigation. With ongoing advancements in nanotechnology and drug delivery, antidiabetic-loaded SLNs hold promise for revolutionizing diabetes therapy and improving patient care
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
